menu search

Bioaegis therapeutics announces fda clearance of ind for its ‘inflammation regulator protein,’ gelsolin, for the treatment of ards

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory ...

January 26, 2023, 7:05 pm

Bioaegis leverages gelsolin’s broad therapeutic applicability by expanding into multiple inflammatory diseases

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatmen...

January 6, 2023, 7:50 pm


Search within

Pages Search Results: